Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head‐to‐head, placebo‐controlled trial

• Published in: BJU international Vol. 107; no. 9; pp. 1432 - 1440
• Main Authors: Kaplan, Steven A., Schneider, Tim, Foote, Jenelle E., Guan, Zhonghong, Carlsson, Martin, Gong, Jason
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.05.2011; Wiley-Blackwell
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; antimuscarinic; Benzhydryl Compounds - administration & dosage; Benzhydryl Compounds - therapeutic use; Biological and medical sciences; Cresols - administration & dosage; Cresols - therapeutic use; Delayed-Action Preparations; efficacy; Epidemiologic Methods; Female; fesoterodine; head‐to‐head; Humans; Male; Medical sciences; Middle Aged; Muscarinic Antagonists - administration & dosage; Muscarinic Antagonists - therapeutic use; Nephrology. Urinary tract diseases; Phenylpropanolamine - administration & dosage; Phenylpropanolamine - therapeutic use; Quality of Life; tolterodine; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive - complications; Urinary Bladder, Overactive - drug therapy; Urinary Incontinence, Urge - drug therapy; Urinary Incontinence, Urge - etiology; Young Adult; Nephrology; Head; Treatment efficiency; Slow release form; Tolterodine; Fesoterodine; Urology; efficacy; Quality of life; Prospective; Anticholinergic agent; Cholinergic receptor; Age of onset; head-to-head; Antimuscarinic agent; antimuscarinic; Placebo; Clinical trial; Muscarinic receptor; Antagonist
• ISSN: 1464-4096; 1464-410X; 1464-410X
• DOI: 10.1111/j.1464-410X.2010.09640.x

Study Type – Therapy (RCT) 
Level of Evidence 1b What’s known on the subject? and What does the study add? A previous trial found greater efficacy with the maximum available dose of fesoterodine 8 mg compared with the maximum available dose of tolterodine ER 4 mg and placebo for improving overactive...